Table 2. Clinical progression glioma group.
| Pathology | Number | ΔG | Time to growth (months), median (IQR) | ΔV, median (IQR) | ||||
|---|---|---|---|---|---|---|---|---|
| CAD | VC | p-Value | CAD | VC | p-Value | |||
| Oligodendroglioma | 7 | 7 | 19 (13–23) | 79 (48–101) | <0.001 | 52% (36%–72%) | 163% (141%–479%) | 0.001 |
| Astrocytoma | 18 | 14 | 12 (10–16) | 33 (26–44) | <0.001 | 50% (37%–76%) | 155% (120%–257%) | 0.001 |
| Mixed glioma | 9 | 8 | 16 (10–20) | 56 (31–70) | <0.001 | 69% (46%–116%) | 286% (203%–537%) | <0.001 |
| All | 34 | 29 | 14 (11–20) | 44 (30–68) | <0.001 | 57% (36%–77%) | 174% (134%–342%) | <0.001 |
ΔG: number of patients whose glioma time to growth detected by computer-assisted diagnosis (CAD) was shorter than that detected by visual comparison (VC). ΔV: percent change in tumor volume from baseline to time point of growth detection. The p-values were generated by the Mann–Whitney–Wilcoxon 2-tail test. The results of CAD were identical to that of VC in 5 patients.